DOP006: Research gaps in diet and nutrition in Inflammatory Bowel Disease. A topical review by ECCOECCO'17 Barcelona 2017
1
DOP008: Dietary manipulation of the healthy human and Colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept studyECCO'17 Barcelona 2017
1
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosisECCO'17 Barcelona 2017
1
DOP010: ECCO Topical Review on Transitional Care in Inflammatory Bowel DiseaseECCO'17 Barcelona 2017
1
DOP011: Risk of opportunistic infection in healthcare personnel with Inflammatory Bowel Disease: A case-control study of the GETAIDECCO'17 Barcelona 2017
1
DOP012: Impact on clinical practice of Epstein-Barr virus infection in patients with Inflammatory Bowel DiseaseECCO'17 Barcelona 2017
1
DOP013: Definition of therapeutic response criteria using MRI in Crohn’s Disease patients treated with anti-TNF therapy: A multicenter prospective study (the IRMA study)ECCO'17 Barcelona 2017
1
DOP014: Transmural healing is better than mucosal healing in Crohn's DiseaseECCO'17 Barcelona 2017
1
DOP015: International differences in gastroenterologists’ perspective on stopping therapy for patients with Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of Inflammatory Bowel Diseases: Results from the multicenter European TEDDY studyECCO'17 Barcelona 2017
1
DOP017: Patterns of anti-TNF use and associated treatment outcomes in Inflammatory Bowel Disease patients: Results from an analysis of Dutch health insurance claims dataECCO'17 Barcelona 2017
1
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADAECCO'17 Barcelona 2017
1
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s Disease: A GEMINI 2 post hoc analysisECCO'17 Barcelona 2017
1
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumabECCO'17 Barcelona 2017
1
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn’s Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension studyECCO'17 Barcelona 2017
1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart reviewECCO'17 Barcelona 2017
1
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortiumECCO'17 Barcelona 2017
1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO'17 Barcelona 2017
1